Market Research Logo

Ovarian Cancer - Pipeline Review, H1 2018

Ovarian Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2018, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 15, 152, 147, 11, 209, 28 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 15, 47 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Ovarian Cancer - Overview
Ovarian Cancer - Therapeutics Development
Ovarian Cancer - Therapeutics Assessment
Ovarian Cancer - Companies Involved in Therapeutics Development
Ovarian Cancer - Drug Profiles
Ovarian Cancer - Dormant Projects
Ovarian Cancer - Discontinued Products
Ovarian Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Ovarian Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
Ovarian Cancer - Pipeline by 4SC AG, H1 2018
Ovarian Cancer - Pipeline by AB Science SA, H1 2018
Ovarian Cancer - Pipeline by AbbVie Inc, H1 2018
Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2018
Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H1 2018
Ovarian Cancer - Pipeline by Agenus Inc, H1 2018
Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2018
Ovarian Cancer - Pipeline by AlfaSigma SpA, H1 2018
Ovarian Cancer - Pipeline by Alkermes Plc, H1 2018
Ovarian Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H1 2018
Ovarian Cancer - Pipeline by Alteogen Inc, H1 2018
Ovarian Cancer - Pipeline by Altor BioScience Corp, H1 2018
Ovarian Cancer - Pipeline by Ambrx Inc, H1 2018
Ovarian Cancer - Pipeline by Amgen Inc, H1 2018
Ovarian Cancer - Pipeline by AnGes Inc, H1 2018
Ovarian Cancer - Pipeline by ANP Technologies Inc, H1 2018
Ovarian Cancer - Pipeline by AntiCancer Inc, H1 2018
Ovarian Cancer - Pipeline by Antigen Express Inc, H1 2018
Ovarian Cancer - Pipeline by Antoxis Ltd, H1 2018
Ovarian Cancer - Pipeline by Aphios Corp, H1 2018
Ovarian Cancer - Pipeline by Aposense Ltd, H1 2018
Ovarian Cancer - Pipeline by Aprea AB, H1 2018
Ovarian Cancer - Pipeline by Arcus Biosciences Inc, H1 2018
Ovarian Cancer - Pipeline by arGEN-X BV, H1 2018
Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H1 2018
Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H1 2018
Ovarian Cancer - Pipeline by ArQule Inc, H1 2018
Ovarian Cancer - Pipeline by Array BioPharma Inc, H1 2018
Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
Ovarian Cancer - Pipeline by Astellas Pharma Inc, H1 2018
Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018
Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2018
Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018
Ovarian Cancer - Pipeline by Athenex Inc, H1 2018
Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
Ovarian Cancer - Pipeline by Avipep Pty Ltd, H1 2018
Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018
Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H1 2018
Ovarian Cancer - Pipeline by Bayer AG, H1 2018
Ovarian Cancer - Pipeline by BeiGene Ltd, H1 2018
Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H1 2018
Ovarian Cancer - Pipeline by BioCancell Ltd, H1 2018
Ovarian Cancer - Pipeline by BioEclipse Therapeutics Inc, H1 2018
Ovarian Cancer - Pipeline by BioMoti Ltd, H1 2018
Ovarian Cancer - Pipeline by Bionomics Ltd, H1 2018
Ovarian Cancer - Pipeline by BioNTech AG, H1 2018
Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018
Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
List of Figures
Number of Products under Development for Ovarian Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report